Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fine-Mist inhalers aim to reach deep lungs in COPD

NCT ID NCT01721291

Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study tests whether a fine-mist inhaler can deliver salbutamol deeper into the lungs than standard inhalers. People with COPD, asthma, and healthy volunteers inhale salbutamol in different particle sizes, some tagged with a radioactive tracer to track where the drug lands. Researchers use imaging and breathing tests to see if the fine mist reaches the small airways and improves breathing. The goal is to guide development of more efficient inhalers for COPD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Salbutamol (albuterol) delivered as a fine-mist aerosol via a special generator, compared with a standard metered-dose inhaler
What this could lead to
If fine-mist droplets reach deeper airways, this could lead to more effective inhalers that better relieve breathlessness in COPD and asthma.
What could go wrong
This is a small early-phase study, so results may not apply to all patients. The fine-mist approach might not improve breathing enough to matter in daily life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

64 people

The number who actually took part.

Started

Oct 2012

Finished

Nov 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- COPD patients, either male or female, over the age of 40 with a clinical diagnosis of COPD with airflow obstruction(FEV1/FVC\<0.7) and post-bronchodilator FEV1\>50% predicted, gas trapping (on lung volume testing), and decreased carbon monoxide transfer factor. Healthy subjects will be nonsmokers(or exsmokers stopped 5 years ago), will have no respiratory disease, normal spirometry and be age-matched to the COPD patients. Asthmatic subjects, either male or female, over the age of 18 with a clinical diagnosis of Asthma with airflow obstruction (FEV1/FVC\<0.7). All patients should be capable of giving informed consent. Exclusion Criteria: 1. Oral corticosteroids taken within last month. 2. Current involvement (or involvement in the last 4 weeks)in clinical trials assessing investigational medicinal products. 3. Previous adverse reaction to short or long acting β2 agonist. 4. Any subject with a contraindication to taking inhaled beta2-adrenoceptor agonists (especially salbutamol) as listed in the British National Formulary will not be entered into this study. 5. Those who have experienced an acute respiratory exacerbation requiring emergency room treatment and/ or hospitalisation within four weeks of visit 1 (screening visit). 6. Pregnant or breastfeeding women. 7. Subjects unable to give Informed Consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Chronic obstructive pulmonary disease Healthy subjects

Contacts and locations

Locations

  • Royal Brompton Hospital & Imperial College London

    London, London, SW3 6LY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.